Results 11 to 20 of about 59,926 (291)
Inhibition of RANKL-Induced Osteoclastogenesis by Novel Mutant RANKL [PDF]
International Journal of Molecular Sciences, 2021 Background: Recently, it was reported that leucine-rich repeat-containing G-protein-coupled receptor 4 (LGR4, also called GPR48) is another receptor for RANKL and was shown to compete with RANK to bind RANKL and suppress canonical RANK signaling during osteoclast differentiation.
Yuria Jang +4 more
openaire +3 more sources
RANKL Expression in Periodontal Disease: Where Does RANKL Come from? [PDF]
BioMed Research International, 2014 Periodontitis is an inflammatory disease characterized by periodontal pocket formation and alveolar bone resorption. Periodontal bone resorption is induced by osteoclasts and receptor activator of nuclear factor-κB ligand (RANKL) which is an essential and central regulator of osteoclast development and osteoclast function.
Bin Chen +5 more
openaire +7 more sources
Osteopetrosis rescue upon RANKL administration to Rankl−/− mice: A new therapy for human RANKL-dependent ARO [PDF]
Journal of Bone and Mineral Research, 2012 Abstract In the last decades the molecular basis of monogenic diseases has been largely unraveled, although their treatment has often remained unsatisfactory. Autosomal recessive osteopetrosis (ARO) belongs to the small group of genetic diseases that are usually treated with hematopoietic stem cell transplantation (HSCT).
LO IACONO N +21 more
core +4 more sources
Relationship between serum RANKL and RANKL in bone
Osteoporosis International, 2011 It is now well accepted that the molecule receptor activator of NFκB ligand (RANKL) and osteoprotegerin play key roles in regulating physiological and pathological bone turnover. There are a large number of published reports of circulating RANKL levels in both health and pathology.
Findlay, D., Atkins, G.
openaire +4 more sources
Targeting RANKL in metastasis [PDF]
BoneKEy Reports, 2014 Acting through its cognate receptor, receptor activator of nuclear factor-κB (RANK), RANK ligand (RANKL) is an essential mediator of osteoclast function and survival. Preclinical data have now firmly established that blockade of tumor-induced osteoclastogenesis by RANKL inhibition will not only protect against bone destruction but will also inhibit the
Dougall, W.C. +2 more
openaire +6 more sources
médecine/sciences, 2008 Given the increasing risk of fractures with aging in western countries, there is a need for the development of safe and efficient anti-osteoporotic drugs for the prevention and treatment of osteoporosis. Recent studies have provided evidence for an essential role of RANKL (Receptor Activator of Nuclear Factor-kappa B Ligand) and its decoy receptor ...
Pierre Marie, Philippe Halbout
openaire +2 more sources
Genetic Polymorphisms of RANK, RANKL and their relation to osteoporosis (Polimorfismos genéticos de RANK y RANKL y su relación con la osteoporosis) [PDF]
, 2012 [eng] Osteoporosis is a systemic skeletal disorder and the most common metabolic bone disease. It is recognized as one of the most prevalent problems facing postmenopausal women in western society. The World Health Organization definition of osteoporosis
Yoskovitz, Guy
core +6 more sources
Gerontology, 2015 Receptor activator of nuclear factor κB (RANK) and its ligand (RANKL) have originally been described for their key roles in bone metabolism and the immune system. Subsequently, it has been shown that the RANKL-RANK system is critical in the formation of mammary epithelia in lactating females and the thermoregulation of the central nervous system. RANKL
Vanja, Nagy, Josef M, Penninger
openaire +2 more sources
Streptococcal Mannose Phosphotransferase System Component IID Is a Novel RANK-Binding Osteoclastogenic Factor. [PDF]
Adv Sci (Weinh)Streptococcal mannose phosphotransferase system component IID (Man‐PTSIID) is identified as a novel RANK‐binding osteoclastogenic factor. By directly binding to RANK and activating NF‐κB independently of TLR2, Man‐PTSIID drives osteoclastogenesis and inflammatory bone destruction, uncovering an unexpected microbial mechanism underlying streptococcal ...
Park C +13 more
europepmc +2 more sources
OSTEOPROTEGERIN, RANK, RANKL [PDF]
Biomedical Papers, 2001 Osteoprotegerin, RANK (Receptor Activator of Nuclear factor kappa B) and RANKL (Receptor Activator of Nuclear faktor kappa B ligand) became the aim of intensive research. RANK is considered as a hematopoietic surface receptor controlling osteoclastogenesis and calcium metabolism.
D, Stejskal +5 more
openaire +2 more sources